Happy to share that our story is out! Science Immunology Our study demonstrates that sustained CD28 signaling, is required to maintain PD-1+ CD8 T cells during chronic antigen stimulation (1/) science.org/doi/10.1126/sc…

how does sBCMA impact the cytolytic activity of anti-BCMA BsAb? Is sBCMA a biomarker of primary resistance and guide for dose-adjusted therapy? Holly Lee addresses all these questions #ASH23 ash.confex.com/ash/2023/webpr…

New issue online! In honor of the #NobelPrize2023 awarded to Katalin Kariko & The Drew Weissman Lab, an essay from Brian Brown, Anthony Fauci, Belkaid Lab & Miriam Merad, MD, PhD tells the story of their transformative discovery: the successes and challenges, and the perseverance and vision that were

Excited to announce the 9th edition of the International Immunoschool. This year's theme is 'Challenges and Opportunities in Cancer Immunotherapy' with talks from Eric Vivier Jonathan Kagan Kate Chiappinelli @chiappinellilab.bsky.social Vinod BalachandranMD Kamphorst Lab & more. Register FREE >>> loom.ly/9no6dhU

Want to know more about how genetic ancestry in different regions influences the levels of a key anti-viral cytokine “type I interferon (IFN)” and how this relates to the severity of viral infections?? Ilona

Happening now...!! Great opportunity to learn about new single cell platforms, techniques, analysis and cutting-edge developments in single cell space!!

MRD as an official endpoint for accelerated approval ODAC votes 12-0 great work by all congratulations!!

The European Commission has approved our first blood cancer medicine for the treatment of relapsed/refractory (R/R) follicular lymphoma or R/R diffuse large B-cell lymphoma, after two or more lines of systemic therapy.

#OctoberIssue | This #Review explores how #SLE #genetics have informed disease pathogenesis, diagnosis and treatment strategies. Hospital for Special Surgery (HSS) HSS Education Institute Yogita Ghodke bit.ly/3zkO1rK

At #ASCO25, we’re presenting research exploring investigational combinations in earlier lines of treatment for relapsed/refractory (R/R) #multiplemyeloma (MM). Learn more about our results in this difficult-to-treat #bloodcancer. bit.ly/43aqVzZ

📢New paper alert in @BloodJournal We present BloodFlow, a method with an unprecedented sensitivity of 10-7 in myeloma. Another step towards meaningful assessment of #MRD in blood #mmsm Congrats Marta Carmen González Díaz-Cano PETHEMA Clínica Universidad de Navarra Cima Universidad de Navarra ashpublications.org/blood/article/…

Huge congratulations!! Amazing team effort 🎉

Latest results from our pivotal CHORD trial for our investigational gene therapy for profound genetic hearing loss were simultaneously published by NEJM and presented at #AAOHNSF2025.

At #ASH25, we're presenting new and updated data from our hematology portfolio and pipeline. Learn more about how this will highlight the next wave of potential novel approaches across a range of blood cancers and disorders.